The FDA is allowing early, expanded access to daraxonrasib, an experimental treatment offering new hope to families facing pancreatic cancer.

According to its developer, Revolution Medicine, the drug nearly doubled survival for patients with advanced disease in a large Phase 3 trial — a notable development as treatment options for pancreatic cancer remain limited.